The Irap syringe contains glass beads.Dr. Garfinkel injects Irap in joints.One of the major inducers of osteoarthritis is the general inflammatory molecule IL-1. It’s an important part of the inflammatory response, but when it’s present in high or prolonged quantities in joints it can be detrimental to the articular cartilage matrix.

Treatments currently available to help combat the clinical effects of IL-1 include intra-articular medications, NSAIDS (phenylbutazone or Banamine®), shockwave therapy, Adequan, Legend, and oral supplements.

But a new treatment called IRAP (Interleukin-1 Receptor Antagonist Protein) blocks the IL-1 molecule from binding to tissues, especially damaged articular cartilage in joints.

The procedure begins by drawing blood from the horse into a special glass syringe. The syringe is specifically prepared with glass beads that stimulate the production of the antagonist protein and an anticoagulant. The blood is incubated for 24 hours and then placed in a centrifuge to separate the serum from the blood. The affected joints are then injected with the serum, which may also be frozen for later use.

 How does it work?

The Irap syringe contains glass beads that stimulate the withe blood cells to produce the anti-imflammatory and regenerative cytokines. The whole blood is incubated overnight and then centrifuged to collect serum. The serum produced is then re-injected into the patient.



Blood collection with irap 50ml syringe under routine aseptic conditions

1-2 syringes are required per patient






Incubate syringe at 98.6F for 24 hours




Centrifuge incubated syringe 10 minutes at 3700 rpm.





Aspirate serum with 20ml syringe





Divide autogous conditioned serum throught filter/adapter into 5ml syringes




Keep syringes in a store package at -0.4F. Shelf life 7 months



Irap therapy has been used on a variety of inflammatory conditions:

  • Joint lameness
  • Tendon and ligament injuries
  • muscle injuries

Has it been tested?

The patented irap therapy has been used around the world in thousands of horses with inflammatory conditions.

In a controlled study at Colorado State University: reasults indicated that there was significant clincal and histologic improvement in osteoarthritis-affected joints of horses following treatment with ACS, compared with placebo treatment. Horses treated with ACS had significant clinical improvement in lameness, unlike the placebo group.

The IRAP treatment offers the potential to stop cartilage matrix from being degraded and increase healing. Please call us today at 619-659-1180 if you believe that your horse is a candidate for IRAP therapy. 

Share this post

Submit to FacebookSubmit to Google PlusSubmit to Twitter